Latest Fund Strategy News

Variscan Mines’ Scoping Study for the San José Mine restart in Spain reveals strong economics, low upfront capital, and an 11-year mine life, setting the stage for zinc and lead production from 2028.

Key Petroleum Ltd has completed a modest 3% share placement but will not proceed with the remaining 13%, leaving questions over its funding strategy.

Canyon Resources has mobilised its surface miner to the Minim Martap site, targeting first bauxite production in early Q2 2026 and shipment by Q3, fully funded despite a failed equity raise.

Activeport Group clarifies that shareholder approvals for director and senior management subscriptions in a recent $6.8 million capital raising have expired, prompting the company to consider alternative funding options.

Deep Yellow Limited has firmly denied recent media speculation about a capital raising, reaffirming its compliance with ASX continuous disclosure rules.

Vintage Energy has secured an extension on its $10 million loan facility with PURE Asset Management, providing financial flexibility to advance drilling and joint venture plans at its Southern Flank gas projects.

FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.

Norwood Systems Limited reported a significant revenue increase for the half-year ended December 2025, alongside a widening net loss and strategic progress with Tier-1 telecom customers. The company secured additional funding and advanced its AI-driven voice platforms in collaboration with global hyperscalers.

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

Wisr Limited reports robust half-year growth with a 23% increase in its loan book and a 14% rise in revenue, setting the stage for expected cash profitability in the second half of FY26.

Elixir Energy has locked in a $10 million debt facility secured against its FY26 R&D tax refund to fund the Lorelle-3 appraisal well activities in Queensland’s Taroom Trough. This financial move aims to bolster working capital during a busy operational period.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.